BIOLASE Announces Delisting From Nasdaq
BIOLASE Announces Delisting From Nasdaq
LAKE FOREST, CA / ACCESSWIRE / June 18, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced that the Company received a notice from Nasdaq that it has determined to delist the shares of the Company's common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq's $2,500,000 minimum stockholders' equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b). Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on June 20, 2024.
2024年6月18日，BIOLASE公司（NASDAQ：BIOL），一家全球领先的牙科激光公司，今天宣布，该公司收到了纳斯达克的通知，纳斯达克已决定将该公司普通股的股票从纳斯达克股票市场摘牌。这是由于未能满足纳斯达克上市规则5550（a）（2）中的1.00美元最低竞价价格上市要求以及未能符合纳斯达克的250万美元最低股东权益的持续上市要求或任何备选要求中的任何一项。该公司普通股在纳斯达克交易所的交易暂停将从2024年6月20日交易开始生效。